The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial reduction in body mass and improve metabolic markers, particular… Read More